| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| Targets |
mAChR
The target is the muscarinic acetylcholine receptor (mAChR). (R)-Oxybutynin competitively antagonizes carbachol-induced contractions and blocks muscarinic receptor–mediated signaling, reducing bladder smooth muscle tone and detrusor overactivity. It binds M1–M4 subtypes with varying affinities. |
|---|---|
| ln Vitro |
In coronary artery smooth muscle cells, oxybutynin chloride (0.1, 0.3, 1, 3, 10, 30, 100 μM; 200 ms) inhibits vascular Kv channels in a concentration-dependent manner without causing an anticholinergic effect[1].
(R)-Oxybutynin inhibits carbachol-induced contractions in bladder smooth muscle and binds human muscarinic receptor subtypes (M1–M4) with IC50 values in the nanomolar range (e.g., M1 IC50 ~0.99 nM in some assays). It also inhibits vascular Kv channels at higher concentrations (IC50 ~11.51 μM), independent of anticholinergic effects. |
| ln Vivo |
For specific [3H]N-methylscopolamine binding, 0.5 and 2 hours later, oxybutynin chloride (27.2 mg/kg; po; single) shows a 2-fold increase in Kd values[2]. This indicates a significant binding of mouse brain muscarinic receptors.
In patients with neurogenic bladder dysfunction, (R)-oxybutynin reduces incontinence episodes and improves urodynamic parameters. It is orally active and is being developed as a potentially better-tolerated enantiomer for overactive bladder. |
| Enzyme Assay |
Muscarinic receptor binding is measured using membranes from M1–M4-expressing cells and a radiolabeled muscarinic antagonist (e.g., [3H]QNB); competition curves with (R)-oxybutynin yield Ki values. Functional antagonism is assessed by carbachol-induced contraction or calcium mobilization.
|
| Cell Assay |
Bladder smooth muscle cells or M1–M4-expressing cells are treated with (R)-oxybutynin before carbachol stimulation; contraction is measured by collagen gel assay, and calcium flux or IP1 accumulation is quantified.
|
| Animal Protocol |
Clinical studies administer (R)-oxybutynin orally; incontinence episodes, urodynamic parameters, and adverse effects (e.g., dry mouth) are assessed. Animal studies use oral dosing in detrusor overactivity models with cystometry.
|
| References |
[1]. Li H, et al. The anticholinergic drug oxybutynin inhibits voltage-dependent K+ channels in coronary arterial smooth muscle cells. Clin Exp Pharmacol Physiol. 2019 Nov;46(11):1030-1036.
[2]. Oki T, et al. Comparative evaluation of central muscarinic receptor binding activity by oxybutynin, tolterodine and darifenacin used to treat overactive bladder. J Urol. 2007 Feb;177(2):766-70. |
| Additional Infomation |
(R)-Hydroxybutyrine is a 4-(diethylamino)but-2-yn-1-ol with the R configuration. It is the source of almost all of the antimuscarinic activity of (racemic)-hydroxybutyrine. It can be used as a cholinergic antagonist, calcium channel blocker, and local anesthetic. It is the enantiomer of exaxibutyrine.
|
| Molecular Formula |
C22H31NO3
|
|---|---|
| Molecular Weight |
393.94700
|
| Exact Mass |
393.207
|
| Elemental Analysis |
C, 73.92; H, 8.74; N, 3.92; O, 13.43
|
| CAS # |
119618-21-2
|
| Related CAS # |
Oxybutynin;5633-20-5;Oxybutynin chloride;1508-65-2;(R)-Oxybutynin hydrochloride;1207344-05-5;Oxybutynin-d11 chloride;1185151-95-4; Oxybutynin;5633-20-5;(R)-Oxybutynin hydrochloride;1207344-05-5;Oxybutynin-d11 chloride;1185151-95-4;(R)-Oxybutynin;119618-21-2; 5633-20-5 (racemate); 1508-65-2 (racemate HCl); 1207344-05-5 (R-isomer HCl); 119618-21-2 (R-isomer); 2738613-22-2 (R-isomer citrate); 119618-22-3 (S-isomer); 2862851-81-6 (R-isomer tartrate); 230949-16-3 (S-isomer HCl)
|
| PubChem CID |
6098167
|
| Appearance |
Typically exists as solid at room temperature
|
| Melting Point |
52-54ºC
|
| LogP |
4.144
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
26
|
| Complexity |
490
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CC#C[C@@H](Cl)O
|
| InChi Key |
XIQVNETUBQGFHX-QFIPXVFZSA-N
|
| InChi Code |
InChI=1S/C22H31NO3/c1-3-23(4-2)17-11-12-18-26-21(24)22(25,19-13-7-5-8-14-19)20-15-9-6-10-16-20/h5,7-8,13-14,20,25H,3-4,6,9-10,15-18H2,1-2H3/t22-/m0/s1
|
| Chemical Name |
4-(diethylamino)but-2-ynyl (2R)-2-cyclohexyl-2-hydroxy-2-phenylacetate
|
| Synonyms |
(r)-oxybutynin; 119618-21-2; Aroxybutynin; (-)-Oxybutynin; Oxybutynin, (-)-; r-oxybutynin; (R)-Oxybutynin Chloride; OXYBUTYNIN, (R)-;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5384 mL | 12.6920 mL | 25.3839 mL | |
| 5 mM | 0.5077 mL | 2.5384 mL | 5.0768 mL | |
| 10 mM | 0.2538 mL | 1.2692 mL | 2.5384 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
